CoChat

Ablation of Cbl-b provides protection against transplanted and spontaneous tumors

Open access
Chiang, Jeffrey Y., Jang, Ihn Kyung, Hodes, Richard, Gu, Hua · 2007 · Journal of Clinical Investigation

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

A significant challenge to efforts aimed at inducing effective antitumor immune responses is that CD8(+) T cells, which play a prominent role in these responses, may be unable to respond to tumors that lack costimulatory signals and that are protected by an immune suppressive environment such as that mediated by TGF-beta produced by tumor cells themselves or by infiltrating Tregs, often resulting in tolerance or anergy of tumor-specific T cells. Here we show that the in vitro activation of Cblb(-/-) CD8(+) T cells does not depend on CD28 costimulation and is resistant to TGF-beta suppression. In vivo studies further demonstrated that Cblb(-/-) mice, but not WT controls, efficiently rejected inoculated E.G7 and EL4 lymphomas that did not express B7 ligands and that introduction of the Cblb(-/-) mutation into tumor-prone ataxia telangiectasia mutated-deficient mice markedly reduced the incidence of spontaneous thymic lymphomas. Immunohistological study showed that E.G7 tumors from Cblb(-/-) mice contained massively infiltrating CD8(+) T cells. Adoptive transfer of purified Cblb(-/-) CD8(+) T cells into E.G7 tumor-bearing mice led to efficient eradication of established tumors. Thus, our data indicate that ablation of Cbl-b can be an efficient strategy for eliciting immune responses against both inoculated and spontaneous tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci29472

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. Somasundaram, 2002, Cancer Res., 62, 5267

Cited by

See all 125

Metadata

Authors
Chiang, J. Y., Jang, I. K., Hodes, R., & Gu, H.
Affiliations
  • National Institutes of Health (US)
  • Columbia University (US)
Venue
Journal of Clinical Investigation
Published
2007-04-02
Volume
117
Issue
4
Pages
1029-1036
ISSN
0021-9738 (ISSN-L)
OpenAlex
W1855158451
Cited by
124
References
32
Citations by year
2026: 7 · 2025: 9 · 2024: 6 · 2023: 3 · 2022: 6 · 2021: 10 · 2020: 6 · 2019: 5 · 2018: 8 · 2017: 7 · 2016: 6 · 2015: 2 · 2014: 6 · 2013: 8 · 2012: 7
FWCI
2.73
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • The Journal of Immunology
Funders
National Institutes of Health
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
Cbl-b, CD8+ T cells, antitumor immunity, CD28 costimulation, TGF-beta, regulatory T cells, tumor rejection, EL4 lymphoma, ATM kinase, adoptive T cell therapy, tumor immunosuppression, B7 ligands
MeSH terms
Animals, Lymphoma, Mice, Inbred C57BL, Neoplasm Transplantation, CD4-Positive T-Lymphocytes, Mice, Knockout, CD8-Positive T-Lymphocytes, Adaptor Proteins, Signal Transducing, Proto-Oncogene Proteins c-cbl, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.